The MHRA has approved trofolastat to identify how far high-risk prostate cancer has spread before treatment, to detect ...

Trofolastat is a prostate-specific membrane antigen-targeting agent cleared for use with Technetium-99m for cancerous lesion detection.

Diagnostic imaging plays an important role in identifying cancerous areas, which may help guide treatment decisions. Trofolastat is combined with the radioactive tracer technetium-99m to form ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

The MHRA has approved the product for three clinical settings, including identifying how far high-risk prostate cancer has spread before treatment, detecting recurrence in patients with rising ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...